

• **Name: Jae-Sook Ahn**

• **Current Position: Associate Professor in Chonnam National University
Hwasun Hospital**

• **Country: South Korea**

• **ICBMT 2022 Presentation Title: The transplant decision, before and after: when and who should be considered and how should be prepared**

• **Educational Background:**

Feb. '01: Graduated from Chonnam University Medical School
Received the M.D. and Bachelor of Medical Science

Feb. '04: Received the Master of Medical Science from Graduate School of Chonnam National University, Korea

Aug. '07: Received Ph.D. in Medicine from Graduate School of Chonnam National University, Korea

• **Professional Experiences:**

Mar. '07-present time: CNUH fund endowed Associate Professor of Internal Medicine
(Department of Hematology-Oncology)
in Chonnam National University Hwasun Hospital, Korea

Feb. '18-Jan. '20: Visiting Professor of Department of Molecular Genetics, University of Toronto,
Canada

Mar. '06-Feb. '07: Fellowship in Department of Hematology-Oncology
in Chonnam National University Hwasun Hospital, Korea

Mar. '02-Feb. '06: Residency in Internal Medicine
at Chonnam National University Hospital

Mar. '01-Feb. '02: Internship at Chonnam National University Hospital

• **Professional Organizations**

The Korean Medical Association

The Korean Association of Internal Medicine

The Korean Society of Hematology

The Korean Cancer Association

• **Main Scientific Publications:**

1. **Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.** Jae-Sook Ahn^{#1,2,3}, TaeHyung Kim^{#3,4}, Sung-Hoon Jung¹, Seo-Yeon Ahn¹, Seung-Yeon Jung⁵, Ga-Young Song¹, Mihee Kim¹, Deok-Hwan Yang¹, Je-Jung Lee¹, SeungHyun Choi², Ja-Yeon Lee², Seong-Kyu Park⁶, Joon Ho Moon⁷, Hui Young Lee^{8,9}, Kyoung Ha Kim^{9,10}, Yu Cai^{9,11}, Seong Yoon Yi^{9,12}, Igor Novitzky-Basso⁹, Zhaolei Zhang^{13,14,15}, Hyeoung-

Joon Kim^{16,17}, Dennis Dong Hwan Kim¹⁸ Bone Marrow Transplant. 2021 May;56(5):1159-1170. doi: 10.1038/s41409-020-01165-x. Epub 2020 Dec 5.

2. [Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone.](#) Ahn JS, Kim T, Kim YK, Cho YC, Cho S, Jung SH, Ahn SY, Jung SY, Yang DH, Lee JJ, Choi S, Lee JY, Shin MG, Yoshida K, Ogawa S, Kim IC, Zhang Z, Kim HJ, Kim DDH. *Exp Hematol*. 2019 Jul;75:26-30. doi: 10.1016/j.exphem.2019.06.001. Epub 2019 Jun 12.
3. [Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.](#) Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Choi SH, Lee JY, Tyndel MS, Shin MG, Lee YJ, Sohn SK, Park SK, Zhang Z, Kim HJ, Kim DDH. *Blood*. 2018 Oct 11;132(15):1604-1613. doi: 10.1182/blood-2018-04-848028. Epub 2018 Aug 14.
4. [Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype.](#) Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Lee JY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Lee YJ, Won JH, Kim SH, Zhang Z, Kim T, Kim DDH. *Oncotarget*. 2017 Dec 22;9(4):4961-4968. doi: 10.18632/oncotarget.23575. eCollection 2018 Jan 12.
5. [5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.](#) Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Michael S, Minden MD, Kim DD. *Oncotarget*. 2017 Jan 31;8(5):8305-8314. doi: 10.18632/oncotarget.14171.
6. [Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.](#) Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. *Ann Hematol*. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z.
7. [Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.](#) Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. *Ann Hematol*. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7.
8. [DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.](#) Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD. *Biol Blood Marrow Transplant*. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.
9. [Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.](#) Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Lee IK, Kim NY, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim N, Yoshida K, Ogawa S, Kim DD. *Haematologica*. 2015 Sep;100(9):e351-3. doi: 10.3324/haematol.2015.126227.